Marksans Pharma Profit & Loss Annual

BSE: 524404 | NSE: MARKSANS | ISIN: INE750C01026 | Sector: Biotechnology & Drugs

325.25 +0.90 (0.28%)Updated : 07 Oct 2026

Research on

Interim Data

Annual Data

Fiscal Period	2026	2025	2024	2023
Period End Date	Mar 26	Mar 25	Mar 24	Mar 23
Total Operating Expense	2,445.19	2,157.43	1,789.16	1,553.60
Diluted Weighted Average Shares	45.34	45.32	45.32	41.54
Gain( Loss)on Saleof Assets	-0.06	-0.03	0.09	-0.26
Depreciation/ Amortization	98.63	83.39	74.27	51.85
Operating Income	505.74	465.42	388.25	298.54
Net Income	417.90	380.58	313.70	266.31
Income Availableto Com Excl Extra Ord	417.90	380.58	313.70	266.31
Other Operating Expenses Total	43.10	16.75	63.75	126.28
Net Income Before Taxes	560.56	503.97	423.53	337.65
Minority Interest	-2.16	-2.04	-1.19	0.99
Net Income After Taxes	420.06	382.62	314.90	265.32
Income Availableto Com Incl Extra Ord	417.90	380.58	313.70	266.31
Costof Revenue Total	1,426.66	1,269.54	1,139.58	945.86
Gross Profit	1,524.28	1,353.31	1,037.82	906.28
Interest Inc( Exp) Net- Non- Op Total	54.88	38.58	35.19	34.92
Unusual Expense( Income)	2.63	-2.28	-	-
Diluted Net Income	417.90	380.58	313.70	266.31
DPS- Common Stock Primary Issue	0.90	0.80	0.60	0.50
Provisionfor Income Taxes	140.49	121.35	108.63	72.33
period Type	-	-	-	-
Net Income Before Extra Items	417.90	380.58	313.70	266.31
Total Revenue	2,950.94	2,622.85	2,177.41	1,852.14
period Length	12.00	12.00	12.00	12.00
Revenue	2,950.94	2,622.85	2,177.41	1,852.14
Selling/ General/ Admin Expenses Total	874.18	790.03	511.56	429.61
Diluted Normalized EPS	9.26	8.36	6.92	6.42
Diluted EPS Excluding Extra Ord Items	9.22	8.40	6.92	6.41
Other Net	-	-	0.00	4.46

*All figures in crores except per share values

Trending Stocks

1,035.00+40.00(4.02%)

2,079.30+29.30(1.43%)

1,246.00+17.00(1.38%)

11,400.00-549.00 (-4.59%)

2,851.05-96.35 (-3.27%)

Related News